Biogen has historically outperformed the market over three decades, but faces current headwinds from biosimilar competition and weak revenue growth. While newer products like Leqembi (Alzheimer's) and high-dose Spinraza show promise with strong growth potential, the company's 2026 guidance projects declining sales. The stock carries heightened risk and is unlikely to deliver strong long-term returns without near-flawless execution.

President Trump signed S. 3971, reauthorizing the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2031. The legislation includes reforms to strengthen national security, accountability, and innovation. Since 1982, these programs have invested over $81 billion into 34,000+ small businesses and supported major companies including Anduril, Qualcomm, Biogen, Illumina, and iRobot.

The dementia therapeutics market is experiencing significant growth driven by emerging disease-modifying treatments for early-stage Alzheimer's and promising therapies for other dementia subtypes. With approximately 55 million people globally affected by dementia, the market is shifting toward proactive intervention with drugs like LEQEMBI and KISUNLA leading the way, while the pipeline shows promise with novel agents targeting diverse symptoms and unmet needs.

Biogen has entered into an agreement with Alloy Therapeutics to accelerate the development of antisense therapies for multiple undisclosed indications. Alloy's AntiClastic ASO platform aims to improve the effectiveness of antisense therapeutics by targeting disease pathways at the RNA level. This partnership follows Alloy's January 2025 collaboration with Sanofi and Biogen's recent acquisition of Apellis Pharmaceuticals for $5.6 billion.

The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.

Major M&A activity dominates the market with McCormick merging with Unilever's Foods business in a $29.1 billion deal, Sysco acquiring Jetro Restaurant Depot for $29 billion, and Eli Lilly acquiring Centessa Pharmaceuticals for $7.8 billion. Meanwhile, QVC faces financial distress and is considering Chapter 11 bankruptcy, while several other companies including IO Biotech and Lipella Pharmaceuticals have filed for bankruptcy.

Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.

U.S. equities staged their strongest rally in weeks on Tuesday following Trump's signals of willingness to end military hostilities with Iran. The S&P 500 advanced 1.8% to 6,456, though it remains down 6.2% for the month. Tech stocks led the recovery with the Nasdaq 100 rising 2%. Despite the rally, the S&P 500 is on track for its worst monthly performance since September 2022.

Biogen has agreed to acquire Apellis Pharmaceuticals for $41 per share in cash, valuing the deal at approximately $5.6 billion. The acquisition includes two FDA-approved therapies (Empaveli and Syfovre) with combined 2025 net sales of $689 million and expected mid-to-high teens growth through 2028. Apellis shares surged 136% to $40.36, while Biogen shares declined 4.60% to $178.94.

Biogen's stock rose 1.51% to $186.62 following FDA approval of a high-dose regimen for Spinraza, a treatment for spinal muscular atrophy (SMA). The approval is based on Phase 2/3 DEVOTE study data showing significant motor function improvements in treatment-naïve infants. Additionally, Biogen announced positive Phase 2 results for litifilimab in cutaneous lupus erythematosus, demonstrating statistically significant improvement versus placebo.

Biogen announced positive Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (CLE), meeting its primary endpoint with an 11.8% higher reduction in disease activity compared to placebo at Week 16. The drug demonstrated rapid improvement and was generally well tolerated, consistent with earlier positive LILAC trial results. Litifilimab received FDA Breakthrough Therapy Designation and could be the first targeted therapy for CLE in 70 years if approved.

The United States District Court for the District of Massachusetts has certified a class action lawsuit on behalf of purchasers of Biogen, Inc. securities during June 8 - July 12, 2021. The action alleges that Biogen and certain officers made material misrepresentations or omitted material facts in violation of federal securities laws. Defendants deny all allegations.